A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia

被引:93
|
作者
Li, Huafang [2 ]
Rui, Qing [1 ]
Ning, Xiaoping [3 ]
Xu, Haiyan [3 ]
Gu, Niufan [2 ]
机构
[1] Xian Janssen Pharmaceut Ltd, CNS, Med Affairs, Beijing 100025, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Shanghai Mental Hlth Ctr, Shanghai 200030, Peoples R China
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
Long-acting injectable; Paliperidone palmitate; PANSS; Risperidone; Schizophrenia; SAFETY; EFFICACY; SCALE;
D O I
10.1016/j.pnpbp.2011.02.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia. Eligible Chinese adults (N = 452) with schizophrenia were randomized (1:1) to either PP (N = 229; deltoid injections on day 1 [150 mg eq.] and day 8 [100 mg eq.]; then once-monthly deltoid or gluteal injections, flexibly dosed [50, 100, or 150 mg eq.]). or RIS-LAI (N = 223; once-biweekly gluteal injections, flexibly dosed [25, 37.5 or 50 mg]). RIS-LAI-treated patients received oral risperidone supplementation (1-6 mg/day) at initiation and with RIS-LAI dose increases. Mean (SD) Positive and Negative Syndrome Scale (PANSS) total score at baseline was 83.2 (12.44). Mean (SD) change from baseline to endpoint in PANSS total scores (primary efficacy measure) was: -23.6 (16.28) for PP group and -26.9 (15.43) for RIS-LAI group. PP was noninferior to RIS-LAI (least squares mean difference [95% CI]: -2.3 [-5.20; 0.63]; predetermined non-inferiority margin: -5.5). Mean (SD) change from baseline to endpoint in Clinical Global Impression-Severity scale score was: -1.5 (1.24; PP group), -1.7 (1.16; RIS-LAI group) and in Personal and Social Performance Scale scores was: 16.8 (14.76; PP group), 18.6 (13.92; RIS-LAI group). The incidence of treatment-emergent adverse events (TEAEs) was similar between the two groups (73% [PP]; 75% [RIS-LAI]). The most common TEAEs were akathisia, tremor, and insomnia. The study demonstrated the noninferiority of PP (50-150 mg eq., flexibly dosed, without oral paliperidone supplementation) to risperidone-LAI (25-50 mg, flexibly dosed, with oral risperidone supplementation) for the treatment of acute schizophrenia in adult Chinese patients. PP injections were generally tolerable, and no new safety signals were detected in this population. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:1002 / 1008
页数:7
相关论文
共 50 条
  • [1] A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia
    Fleischhacker, W. Wolfgang
    Gopal, Srihari
    Lane, Rosanne
    Gassmann-Mayer, Cristiana
    Lim, Pilar
    Hough, David
    Remmerie, Bart
    Eerdekens, Marielle
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2012, 15 (01): : 107 - 118
  • [2] A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia
    Pandina, Gahan
    Lane, Rosanne
    Gopal, Srihari
    Gassmann-Mayer, Cristiana
    Hough, David
    Remmerie, Bart
    Simpson, George
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (01): : 218 - 226
  • [3] A comparative randomized, open-label, rater-blinded study of paliperidone palmitate and risperidone long-acting injectable therapy in patients with schizophrenia
    Li, H.
    Rui, Q.
    Ning, X.
    Xu, H.
    Gu, N.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 167 - 167
  • [4] Long-acting injectable paliperidone palmitate in a haemodialysis patient with schizophrenia
    Lin, Jia-Hong
    Tsai, Tsung-Huang
    Lee, Chia-Shun
    Yang, Ya-Hui
    Chen, Kuang-Peng
    Tung, Chun-Liong
    Tsai, Jui-Hsiu
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (08): : 829 - 830
  • [5] A randomized, double-blind study of paliperidone palmitate and risperidone long-acting therapy in schizophrenia
    Pandina, G.
    Lane, R.
    Gopal, S.
    Gassmann-Mayer, C.
    Hough, D.
    Remmerie, B.
    Simpson, G.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S481 - S482
  • [6] EVALUATION OF PALIPERIDONE PALMITATE LONG-ACTING INJECTABLE THERAPY BY DURATION OF ILLNESS IN PATIENTS WITH SCHIZOPHRENIA
    Brown, B.
    Turkoz, I.
    Mancevski, B.
    Mathews, M.
    Reeve-Parker, K.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2017, 51 : 161 - 161
  • [7] Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 198 - 198
  • [8] Evaluation of Paliperidone Palmitate Long-Acting Injectable Therapy by Duration of Illness in Patients With Schizophrenia
    Brown, Brianne
    Turkoz, Ibrahim
    Mancevski, Branislav
    Mathews, Maju
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 212S - 212S
  • [9] Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
    Alphs, Larry
    Bossie, Cynthia A.
    Sliwa, Jennifer Kern
    Fu, Dong-Jing
    Ma, Yi-Wen
    Hulihan, Joseph
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2013, 9 : 341 - 350
  • [10] COST OF LONG-ACTING RISPERIDONE INJECTION VERSUS LONG-ACTING PALIPERIDONE PALMITATE IN PATIENTS WITH SCHIZOPHRENIA IN RUSSIA
    Omelyanovsky, V
    Avxentyeva, M.
    Ivakhnenko, O.
    Khailov, P.
    Tsfasman, F. M.
    Krysanov, I
    Zorin, N.
    VALUE IN HEALTH, 2012, 15 (07) : A338 - A338